Qiagen optimistic

GERMAN biotechnology firm Qiagen hopes its revenue in China will nearly double this year with increasing demand for molecular testing. The company, which provides sample and assay technologies for research institutions and pharmaceutical firms, has seen revenue increase more than 90 percent in China in the past year while that of the Asian Pacific region jumped about 40 percent. Asia Pacific now contributes 15 percent of its global revenue, according to Victor Shi, president of Qiagen Asia Pacific. The company has production bases in Shenzhen and Beijing.